Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 2 Published - 14:00 UTC    08:00 EST    02-January-2001      
Issue 2 Next Update - 14:00 UTC 08:00 EST    03-January-2001      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya



















Back To Vidyya New American Heart Association (AHA) Guidelines Indicate People With Diabetes Can Prevent Stroke With Ramipril


Survey Reveals That Although Diabetics Are At Increased Risk For Stroke And Heart Disease, Many May Be Missing Benefits Of Cardiovascular Protection

New guidelines issued yesterday by the Stroke Council of the American Heart Association (AHA) and published in Circulation and Stroke recommend use of ramipril -- Altace® -- in at risk people with diabetes to prevent stroke. These recommendations are based on data from the HOPE (Heart Outcomes Prevention Evaluation) Study, which demonstrated that people with diabetes can reduce their risk of stroke by 33 percent, even if they are already taking other medications.

According to a new International Communications Research survey commissioned by the Chicago Center for Clinical Research more than two-thirds of Americans are unaware that, like obesity and smoking, diabetes is a major risk factor for cardiovascular disease. Experts from the Chicago Center for Clinical Research say that by failing to make the link, many people with diabetes are missing the benefits of available preventive therapies such as Altace, for heart attack and stroke.

Nearly 40% of the survey respondents thought that the number one killer of people with diabetes is kidney failure. Only 14 percent knew that the correct answer is cardiovascular disease, the leading killer of all Americans. More than 60 percent of people with diabetes die of some form of heart or blood vessel disease compared to 40 percent of the general population. People with diabetes are two to four times more likely to suffer from heart disease, yet the survey found that few Americans know that this increased risk exists. In addition, people with diabetes are also two to four times more likely to suffer a stroke.

"It's frightening that so few people understand the very direct impact diabetes has on their risk for suffering a heart attack or stroke," said Michael Davidson, MD, Chief Executive Officer and President, Chicago Center for Clinical Research. "These new guidelines make it clear that simply adding Altace to a current treatment regimen can give added protection for reducing the risk of stroke. However, more people need to become aware of the link between diabetes and cardiovascular disease to ensure that they are doing as much as they can to reduce this risk."

"Approximately 16 million Americans -- about one in every 12 adults -- suffers from diabetes," said Dr. Jeffrey Probstfield, M.D., Professor of Medicine, University of Washington and Investigator of the Heart Outcomes Prevention Evaluation (HOPE) Study. "The incidence of diabetes greatly increases with age. More than one in six Americans age 65 and over has diabetes. Because the risk of cardiovascular disease also increases with age, the threat of cardiovascular disease should be a particular concern for older adults with diabetes."

The HOPE Trial

The HOPE trial included a subset of 3,500 patients who had diabetes plus at least one other cardiovascular risk factor. The study compared the outcomes of patients getting Altace® (ramipril) or a placebo. The study medication was added to other therapies for cardiovascular disease, such as aspirin, beta blockers or lipid lowering agents.

"In patients with diabetes who took Altace, the risk reduction for stroke was 33%; for heart attack it was 22%; and for cardiovascular death it was 37%. The HOPE results also showed that Altace protects people with diabetes beyond just reducing risk of events. Patients treated with Altace have a 22% reduction in the need for laser eye therapy and a 16% lower risk of permanent kidney damage," says Dr. Probstfield. The results of the HOPE trial were published earlier this year in The New England Journal of Medicine.

About the Chicago Center for Clinical Research

The survey was commissioned by the Chicago Center for Clinical Research through a grant from Wyeth-Ayerst Laboratories and King Pharmaceuticals. The survey of 1,961 Americans was conducted by International Communications Research.


Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 
Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.